Who Supplies Iron to India from ITALY

To import finished pharmaceutical formulations containing iron into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, including composition, manufacturing process, and stability data. The CDSCO evaluates the safety, efficacy, and quality of the product before granting approval. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months. For products under HS Code 30049099, specific requirements include compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The foreign manufacturer must also provide a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, Government of India, and ensure that the product meets the standards set by the Indian Pharmacopoeia. Additionally, the manufacturer must have a valid manufacturing license from the country of origin and provide a Free Sale Certificate to demonstrate that the product is freely sold in the domestic market of the exporting country. The application for import registration and license must be submitted to the CDSCO, and the process involves scrutiny of the submitted documents, which can take several months. It is advisable to initiate the registration process well in advance to account for any unforeseen delays.

Imported finished pharmaceutical formulations containing iron are subject to quality testing and batch certification requirements upon arrival in India. The Central Drugs Standard Control Organization (CDSCO) mandates that each batch of imported drugs undergoes testing at a CDSCO-approved laboratory to ensure compliance with Indian Pharmacopoeia standards. The testing includes assessments of identity, purity, strength, and quality. The manufacturer must provide a Certificate of Analysis (CoA) for each batch, detailing the results of these tests. Stability data, particularly in accordance with International Council for Harmonisation (ICH) guidelines for Zone IV conditions, must also be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity of the product and ensure that it matches the approved specifications. If a batch fails to meet the required standards, it may be rejected, destroyed, or returned to the country of origin, depending on the severity of the non-compliance. Therefore, it is crucial for the foreign manufacturer to ensure that all documentation is accurate and that the product meets all quality standards before shipment to avoid delays and additional costs.

Between 2024 and 2026, the Central Drugs Standard Control Organization (CDSCO) has implemented several regulatory updates affecting the import of finished pharmaceutical formulations containing iron. Notably, on April 8, 2025, the CDSCO mandated that all imported drugs, including finished formulations, must obtain an Import Registration Certificate and an Import License as per the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. This requirement aims to streamline the procedure for the transfer of drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA) for sale and distribution. The CDSCO emphasized that banned drugs manufactured in SEZs for export purposes are not allowed for transfer to the DTA. Additionally, the CDSCO has been actively enforcing compliance with the Public Health and Safety (PHS) guidelines, which include stringent quality control measures and post-import monitoring to ensure the safety and efficacy of imported pharmaceutical products. These regulatory changes reflect India's commitment to enhancing the quality and safety of pharmaceutical imports and align with global standards.

India imports finished pharmaceutical formulations containing iron primarily due to the demand for specialized dosage forms and patented or branded products not manufactured domestically. The domestic pharmaceutical industry may lack the capacity or technology to produce certain iron formulations, leading to reliance on imports to meet patient needs. The market size for iron formulations in India is substantial, with a total export market of $487.6 million across 943 exporters to 174 countries. This indicates a significant demand for iron formulations, both domestically and internationally. The importation of these formulations ensures the availability of a diverse range of products, catering to various therapeutic requirements and patient preferences.

The import duty structure for finished pharmaceutical formulations containing iron under HS Code 30049099 in India includes a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable, resulting in an effective duty rate of 11%. The Integrated Goods and Services Tax (IGST) is levied at 12% on the total value, including the BCD and SWS. Therefore, the total landed duty percentage for such imports is approximately 23.536%. There are no additional duties, such as Anti-Dumping Duty, applicable to these products. Exemptions or concessional rates may apply under specific Free Trade Agreements (FTAs) or bilateral agreements; however, as of the latest available data, no such exemptions are specified for Italy-origin products under HS Code 30049099.

India sources finished pharmaceutical formulations containing iron from Italy due to several competitive advantages. Italian manufacturers are known for producing high-quality, innovative formulations that meet international standards. Italy's pharmaceutical industry has a strong reputation for research and development, leading to the availability of patented and specialized dosage forms not readily available from other suppliers. While other countries like China, Germany, and the United States also export iron formulations to India, Italy's emphasis on quality, regulatory compliance, and innovation positions it favorably in the Indian market. Italy's share in India's pharmaceutical imports is significant, reflecting the trust and preference Indian buyers have for Italian products.